Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
The Journal of Headache and Pain
Published in: The Journal of Headache and Pain 1/2011

Open Access 01-02-2011 | Original

Protection of flunarizine on cerebral mitochondria injury induced by cortical spreading depression under hypoxic conditions

Authors: Fengpeng Li, Enchao Qiu, Zhao Dong, Ruozhuo Liu, Shiwen Wu, Shengyuan Yu

Published in: The Journal of Headache and Pain | Issue 1/2011

Login to get access

Abstract

A rat cortical spreading depression (CSD) model was established to explore whether cerebral mitochondria injury was induced by CSD under both normoxic and hypoxic conditions and whether flunarizine had a protective effect on cerebral mitochondria. SD rats, which were divided into seven groups, received treatment as follows: no intervention (control Group I); 1 M NaCl injections (Group II); 1 M KCl injections (Group III); intraperitoneal flunarizine (3 mg/kg) 30 min before KCl injections (Group IV); 14% O2 inhalation before NaCl injections (Group V); 14% O2 inhalation followed by KCl injections (Group VI); 14% O2 inhalation and intraperitoneal flunarizine followed by KCl injections (Group VII). Following treatment, brains were removed for the analysis of mitochondria transmembrane potential (MMP) and oxidative respiratory function after recording the number, amplitude and duration of CSD. The duration of CSD was significantly longer in Group VI than that in Group III. The number and duration of CSD in Group VII was significantly lower than that in Group VI. MMP in Group VI was significantly lower than that in Group III, and MMP in Group VII was significantly higher than that in Group VI. State 4 respiration in Group VI was significantly higher than that in Group III, and state 3 respiration in Group VII was significantly higher than that in Group VI. Respiration control of rate in Group VII was also significantly higher than that in Group VI. Thus, we concluded that aggravated cerebral mitochondria injury might be attributed to CSD under hypoxic conditions. Flunarizine can alleviate such cerebral mitochondria injury under both normoxic and hypoxic conditions.
Literature
1.
Leao AAP (1944) Spreading depression of activity in cerebral cortex. J Neurophysiol 7:359–390
2.
Haghir H, Kovac S, Speckmann EJ, Zilles K, Gorji A (2009) Patterns of neurotransmitter receptor distributions following cortical spreading depression. Neuroscience 163:1340–1352, 19665048, 10.1016/j.neuroscience.2009.07.067, 1:CAS:528:DC%2BD1MXht1GmsL7NCrossRefPubMed
3.
Chang JC, Shook LL, Biag J, Nguyen EN, Toga AW, Charles AC, Brennan KC (2010) Biphasic direct current shift, haemoglobin desaturation and neurovascular uncoupling in cortical spreading depression. Brain 133:996–1012, 20348134, 10.1093/brain/awp338PubMedCentralCrossRefPubMed
4.
Piilgaard H, Lauritzen M (2009) Persistent increase in oxygen consumption and impaired neurovascular coupling after spreading depression in rat neocortex. J Cereb Blod Flow Metab 29:1517–1527, 10.1038/jcbfm.2009.73, 1:CAS:528:DC%2BD1MXhtVKnurvMCrossRef
5.
Funke F, Kron M, Dutschmann M, Müller M (2009) Infant brain stem is prone to the generation of spreading depression during severe hypoxia. J Neurophysiol 101:2395–2410, 19261708, 10.1152/jn.91260.2008CrossRefPubMed
6.
Takano T, Tian GF, Peng W, Lou N, Lovatt D, Hansen AJ, Kasischke KA, Nedergaard M (2007) Cortical spreading depression causes and coincides with tissue hypoxia. Nat Neurosci 10:754–762, 17468748, 10.1038/nn1902, 1:CAS:528:DC%2BD2sXls1KgsbY%3DCrossRefPubMed
7.
Sonn J, Mayevsky A (2000) Effects of brain oxygenation on metabolic, hemodynamic, ionic and electrical responses to spreading depression in the rat. Brain Res 882:212–216, 11056202, 10.1016/S0006-8993(00)02827-4, 1:CAS:528:DC%2BD3cXns12ns7Y%3DCrossRefPubMed
8.
Ouyang YB, Xu LJ, Sun YJ, Giffard RG (2006) Overexpression of inducible heat shock protein 70 and its mutants in astrocytes is associated with maintenance of mitochondrial physiology during glucose deprivation stress. Cell Stress Chaperones 11:180–186, 16817324, 10.1379/CSC-182R.1, 1:CAS:528:DC%2BD28XntF2htbc%3DPubMedCentralCrossRefPubMed
9.
Bartolini M, Baruffaldi R, Paolino I, Silvestrini M (2005) Cerebral blood flow changes in the different phases of migraine. Funct Neurol 20:209–211, 16483463PubMed
10.
Lauritzen M, Olsen TS, Lassen NA, Paulson OB (1983) Regulation of regional cerebral blood flow during and between migraine attacks. Ann Neurol 14:569–572, 6418059, 10.1002/ana.410140512, 1:STN:280:DyaL2c%2FnvVeluw%3D%3DCrossRefPubMed
11.
Lauritzen M (2001) Cortical spreading depression in migraine. Cephalalgia 21:757–760, 11595007, 10.1046/j.1468-2982.2001.00244.x, 1:STN:280:DC%2BD3MrkvVKkug%3D%3DCrossRefPubMed
12.
Dalkara T, Zervas NT, Moskowitz MA (2006) From spreading depression to the trigeminovascular system. Neurol Sci 27:S86–S90, 16688636, 10.1007/s10072-006-0577-zCrossRefPubMed
13.
Mayevsky A, Doron A, Manor T, Mellin S, Zarchin N, Ouaknine GE (1996) Cortical spreading depression recorded from the human brain using a multiparametric monitoring system. Brain Res 740:268–274, 8973824, 10.1016/S0006-8993(96)00874-8, 1:CAS:528:DyaK28Xmslymtrc%3DCrossRefPubMed
14.
Lauritzen M, Olsen TS, Lassen NA, Paulson OB (1983) Changes in regional cerebral blood flow during the course of classic migraine attacks. Ann Neurol 13:633–641, 6881926, 10.1002/ana.410130609, 1:STN:280:DyaL3s3otFGitQ%3D%3DCrossRefPubMed
15.
Olesen J, Larsen B, Lauritzen M (1981) Focal hyperemia followed by spreading oligemia and impaired activation of rCBF in classic migraine. Ann Neurol 9:344–352, 6784664, 10.1002/ana.410090406, 1:STN:280:DyaL3M7ot1yhsg%3D%3DCrossRefPubMed
16.
Woods RP, Iacoboni M, Mazziotta JC (1994) Brief report: bilateral spreading cerebral hypoperfusion during spontaneous migraine headache. N Engl J Med 331:1689–1692, 7969360, 10.1056/NEJM199412223312505, 1:STN:280:DyaK2M%2FlvFehug%3D%3DCrossRefPubMed
17.
Gelmers HJ (1985) Calcium-channel blockers in the treatment of migraine. Am J Cardiol 55:139B–143B, 3881906, 10.1016/0002-9149(85)90622-8, 1:STN:280:DyaL2M7hvV2kug%3D%3DCrossRefPubMed
18.
Reveiz-Herault L, Cardona AF, Ospina EG, Carrillo P (2003) Effectiveness of flunarizine in the prophylaxis of migraine: a meta-analytical review of the literature. Rev Neurol 36:907–912, 12766861, 1:STN:280:DC%2BD3s3ksVansg%3D%3DPubMed
19.
Grotemeyer KH, Schlake HP, Husstedt IW (1988) Prevention of migraine with metoprolol and flunarizine. A double-blind crossover study. Nervenarzt 59:549–552, 3054595, 1:STN:280:DyaL1M%2FktVCjsg%3D%3DPubMed
20.
Ludin HP (1989) Flunarizine and propanolol in the treatment of migraine. Headache 29:219–224, 2654068, 10.1111/j.1526-4610.1989.hed22904219.x, 1:STN:280:DyaL1M3jtlOhsg%3D%3DCrossRefPubMed
21.
Shimell CJ, Fritz VU, Levien SL (1990) A comparative trial of flunarizine and propranolol in the prevention of migraine. S Afr Med J 77:75–77, 2404346, 1:STN:280:DyaK3c7hsleitg%3D%3DPubMed
22.
Lutschg J, Vassella F (1990) The treatment of juvenile migraine using flunarizine or propranolol. Schweiz Med Wochenschr 120:1731–1736, 2251492, 1:STN:280:DyaK3M%2Fmsl2ruw%3D%3DPubMed
23.
Sørensen PS, Larsen BH, Rasmussen MJ, Kinge E, Iversen H, Alslev T, Nøhr P, Pedersen KK, Schrøder P, Lademann A (1991) Flunarizine versus metoprolol in migraine prophylaxis: a double-blind, randomized parallel group study of efficacy and tolerability. Headache 31:650–657, 1769820, 10.1111/j.1526-4610.1991.hed3110650.xCrossRefPubMed
24.
Gawel MJ, Kreeft J, Nelson RF, Simard D, Arnott WS (1992) Comparison of the efficacy and safety of flunarizine to propranolol in the prophylaxis of migraine. Can J Neurol Sci 19:340–345, 1393843, 1:STN:280:DyaK3s%2FgslGhsg%3D%3DPubMed
25.
Verspeelt J, Locht P, Amery WK (1996) Post-marketing cohort study comparing the safety and efficacy of flunarizine and propranolol in the prophylaxis of migraine. Cephalalgia 16:328–336, 8869768, 10.1046/j.1468-2982.1996.1605328.x, 1:STN:280:DyaK2s%2FitlCjug%3D%3DCrossRefPubMed
26.
Bordini CA, Arruda MA, Ciciarelli MC, Speciali JG (1997) Propranolol vs flunarizine vs flunarizine plus propranolol in migraine without aura prophylaxis. A double-blind trial. Arq Neuropsiquiatr 55:536–541, 9629401, 1:STN:280:DyaK1c3ptlSntA%3D%3DCrossRefPubMed
27.
Holmes B, Brogden RN, Heel RC, Speight TM, Avery GS (1984) Flunarizine a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use. Drugs 27:6–44, 6141044, 10.2165/00003495-198427010-00002, 1:STN:280:DyaL2c7gvVWgtQ%3D%3DCrossRefPubMed
28.
Moskowitz MA, Nozaki K, Kraig RP (1993) Neocortical spreading depression provokes the expression of c-fos protein-like immunoreactivity within trigeminal nucleus caudalis via trigeminovascular mechanisms. J Neurosci 13:1167–1177, 8382735, 1:CAS:528:DyaK3sXhvVCisb0%3DPubMedCentralPubMed
29.
Clark JB, Nicklas WJ (1970) The metabolism of rat brain mitochondria. J Biol Chem 245:4724–4731, 4393961, 1:CAS:528:DyaE3cXltVGns7s%3DPubMed
30.
Chávez JZ, Pichiule P, Boero J, Arregui A (1995) Reduced mitochondrial respiration in mouse cerebral cortex during chronic hypoxia. Neurosci Lett 193:169–172, 7478175, 10.1016/0304-3940(95)11692-PCrossRefPubMed
31.
Chance B, Williams GR (1956) The respiratory chain and oxidative phosphorylation. Adv Enzymol 17:65–134, 1:CAS:528:DyaG2sXktlKgsw%3D%3D
32.
Emaus RK, Grunwald R, Lemasters JJ (1986) Rhodamine 123 as a probe of transmembrane potential in isolated rat-liver mitochondria: spectral and metabolic properties. Biochim Biophys Acta 850:436–448, 2873836, 10.1016/0005-2728(86)90112-X, 1:CAS:528:DyaL28XltFWgt7c%3DCrossRefPubMed
33.
Ayata C (2009) Spreading depression: from serendipity to targeted therapy in migraine prophylaxis. Cephalalgia 29:1097–1114, 10.1111/j.1468-2982.2009.01982.xCrossRef
34.
Mayevsky A, Doron A, Manor T, Meilin S, Zarchin N, Ouaknine GE (1996) Cortical spreading depression recorded from the human brain using a multiparametric monitoring system. Brain Res 740:268–274, 8973824, 10.1016/S0006-8993(96)00874-8, 1:CAS:528:DyaK28Xmslymtrc%3DCrossRefPubMed
35.
Strong AJ, Fabricius M, Boutelle MG, Hibbins SJ, Hopwood SE, Jones R, Parkin MC, Lauritzen M (2002) Spreading and synchronous depressions of cortical activity in acutely injured human brain. Stroke 33:2738–2743, 12468763, 10.1161/01.STR.0000043073.69602.09CrossRefPubMed
36.
Charles A, Brennan K (2009) Cortical spreading depression-new insights and persistent questions. Cephalalgia 29:1115–1124, 19735537, 10.1111/j.1468-2982.2009.01983.x, 1:STN:280:DC%2BD1MngvVKisw%3D%3DCrossRefPubMed
37.
Lauritzen M, Trojaborg W, Olesen J (1981) EEG during attacks of common and classical migraine. Cephalalgia 1:63–66, 7346174, 10.1111/j.1468-2982.1981.tb00010.x, 1:STN:280:DyaL383lvFehsA%3D%3DCrossRefPubMed
38.
Ayata C, Jin H, Kudo C, Dalkara T, Moskowitz MA (2006) Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol 59:652–661, 16450381, 10.1002/ana.20778, 1:CAS:528:DC%2BD28XktFWjsrY%3DCrossRefPubMed
39.
Wauquier A, Ashton D, Marrannes R (1985) The effects of flunarizine in experimental models related to the pathogenesis of migraine. Cephalalgia 5(Suppl 2):119–123, 4016924PubMed
40.
Somjen GG (2001) Mechanisms of spreading depression and hypoxic spreading depression-like depolarization. Physiol Rev 81:1065–1096, 11427692, 1:CAS:528:DC%2BD3MXlt1Ohsr8%3DPubMed
41.
Wadman WJ, Juta AJA, kamphuis W, Somjen GG (1992) Current source density of sustained potential shifts associated with electrographic seizures and with spreading depression in rat hippocampus. Brain Res 570:85–91, 1617432, 10.1016/0006-8993(92)90567-S, 1:STN:280:DyaK38zhsV2isg%3D%3DCrossRefPubMed
42.
Jing J, Aitken PG, Somjen GG (1993) Role of calcium channels in spreading depression in rat hippocampal slices. Brain Res 604:251–259, 8384511, 10.1016/0006-8993(93)90376-X, 1:CAS:528:DyaK3sXhs1Gqtb8%3DCrossRefPubMed
43.
Leone M, Grazzi L, La Mantia L, Bussone G (1991) Flunuaizine in migraine: a minireview. Headache 31:388–391, 1889980, 10.1111/j.1526-4610.1991.hed3106388.x, 1:STN:280:DyaK3MzmsFKjtw%3D%3DCrossRefPubMed
44.
Members of the task force, Ever S, Afra J, Frese A, Goadsby PJ, Linde M, May A, Sándor PS (2006) EFNS guideline on the drug treatment of migraine-report of an EFNS task force. Eur J Neurol 13:560–572, 10.1111/j.1468-1331.2006.01411.xCrossRef
45.
Richter F, Ebersberger A, Schaible HG (2002) Blockade of voltage-gated calcium channels in rat inhibits repetitive cortical spreading depression. Neurosci Lett 334:123–126, 12435487, 10.1016/S0304-3940(02)01120-5, 1:CAS:528:DC%2BD38XosFClu7g%3DCrossRefPubMed
46.
Shimazawa M, Hara H, Watano T, Sukamoto T (1995) Effects of Ca2+ channel blockers on cortical hypoperfusion and expression of c-Fos-like immunoreactivity after cortical spreading depression in rats. Br J Pharmacol 115:1359–1368, 8564192, 1:CAS:528:DyaK2MXns1Wgsrw%3DPubMedCentralCrossRefPubMed
47.
Nedergaard M, Hansen AJ (1988) Spreading depression is not associated with neuronal injury in the normal brain. Brain Res 449:395–398, 3395856, 10.1016/0006-8993(88)91062-1, 1:STN:280:DyaL1c3ot1Smtw%3D%3DCrossRefPubMed
48.
Pomper JK, Haack S, Petzold GC, Buchheim K, Gabriel S, Hoffmann U, Heinemann U (2006) Repetitive normoxic spreading depression like events result in cell damage in juvenile hippocampal slice cultures. J Neurophysiol 95:355–368, 16177179, 10.1152/jn.00186.2005CrossRefPubMed
49.
Mies G, Paschen W (1984) Regional changes of blood flow, glucose, and ATP content determined on brain sections during a single passage of spreading depression in rat brain cortex. Exp Neurol 84:249–258, 6714339, 10.1016/0014-4886(84)90222-X, 1:CAS:528:DyaL2cXktVCksL4%3DCrossRefPubMed
50.
Hashimoto M, Takeda Y, Sato T, Kawahara H, Nagano O, Hirakawa M (2000) Dynamic changes of NADH fluorescence images and NADH content during spreading depression in the cerebral cortex of gerbils. Brain Res 87:294–300, 10.1016/S0006-8993(00)02509-9CrossRef
51.
Vergun O, Vltyakova TV, Reynolds IJ (2003) Spontaneous changes in mitochondrial membrane potential in single isolated brain mitochondria. Biophys J 85:3358–3366, 14581237, 10.1016/S0006-3495(03)74755-9, 1:CAS:528:DC%2BD3sXptFWqs7Y%3DPubMedCentralCrossRefPubMed
52.
Sangiorgi s, Mochi M, Riva R, Gortelli P, Monari L, Pierangeli G, Montagna P (1994) Abnormal platelet mitochondrial function in patients affected by migraine with and without aura. Cephalalgia 14:21–23, 8200018, 10.1046/j.1468-2982.1994.1401021.x, 1:STN:280:DyaK2c3lvVKqsQ%3D%3DCrossRefPubMed
53.
Magis D, Ambrosini A, Sándor P, Jacquy J, Laloux P, Schoenen J (2007) A randomized double-blind placebo-controlled trial of thioctic acid in migraine prophylaxis. Headache 47:52–57, 17355494, 10.1111/j.1526-4610.2006.00626.xCrossRefPubMed
Metadata
Title
Protection of flunarizine on cerebral mitochondria injury induced by cortical spreading depression under hypoxic conditions
Authors
Fengpeng Li
Enchao Qiu
Zhao Dong
Ruozhuo Liu
Shiwen Wu
Shengyuan Yu
Publication date
01-02-2011
Publisher
Springer Milan
Published in
The Journal of Headache and Pain / Issue 1/2011
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI
https://doi.org/10.1007/s10194-011-0300-1

Other articles of this Issue 1/2011

The Journal of Headache and Pain 1/2011 Go to the issue

Original

Risk factors of migraine-related brain white matter hyperintensities: an investigation of 186 patients

Review Article

Why pharmacokinetic differences among oral triptans have little clinical importance: a comment

Editorial

Dispute settlement understanding on the use of BOTOX® in chronic migraine

Review Article

Overview of diagnosis and management of paediatric headache. Part I: diagnosis

Original

Migraine and sleep apnea in the general population

Commentary

What do the patients with medication overuse headache expect from treatment and what are the preferred sources of information?